TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00344825

Intervention type: DRUG
Intervention: Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)
Description: Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.~QoL at baseline, Change in QoL over time evaluated using an analysis of Variance.
Study: NCT04079725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined trabeculotomy-trabeculectomy with mitomycin c
Description: Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases then histopathological examination of iris tissue to detect the nature of the disease
Study: NCT02164188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flourishing protocol
Description: This intervention is based on relaxation, well-being promotion, meditation practices, positive psychology principles. The format is 1hour and half meetings during 8 weeks, and daily practices. MP3 audios are presented for daily practices.
Study: NCT00599313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg/day orally each of Days 1-28 of each 6 week cycle
Study: NCT04338997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IZD174
Description: Small molecule inhibitor of NLRP3
Study: NCT02035293

Intervention type: OTHER
Group type: OTHER
Intervention: PEP
Study: NCT03403517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery
Study: NCT04370899

Intervention type: OTHER
Intervention: lifestyle assessment
Description: A semi-quantitative assessment of the consumption of different food groups will be carried out using a frequency questionnaire validated by the Spanish population27. This questionnaire consists of 137 food items and will be obtained by the dietitian of our Unit (see annex).~The child population and/or their parents will be instructed on how to fill the data in the food diary for a period of 3 days, in order to be able to analyse the nutritional composition of the intake and the effect on the lipid profile. The first food register, will be obtained at the collection visit before starting any type of treatment. Another food diary will be included after one year.~Physical activity will be collected from the Minnesota Test and we will ask about the consumption of tobacco.
Study: NCT02373930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
Study: NCT02654509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104
Description: Eastern Equine Encephalitis Vaccine, Inactivated, Dried
Study: NCT00258661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: In addition to conventional treatment for pneumonia, a 10-minute standardized OMT protocol + 5-minute nonstandardized component was performed twice daily for the duration of hospitalization.
Study: NCT00258661

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Light-touch Treatment
Description: In addition to conventional treatment for pneumonia, a 10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs was performed twice daily for the duration of hospitalization.
Study: NCT02373930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
Study: NCT01635647

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 ME-TRAP and MVA ME-TRAP
Description: ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 1 x 10\^8 pfu heterologous prime-boost immunisation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies vaccine
Description: Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab
Study: NCT00126217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacille Calmette Guerin (BCG)
Description: 0,1 ml, revaccination at 19 months of age
Study: NCT00992836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H1N1) 2009 monovalent vaccine
Description: Two doses of vaccine, delivered 21 days apart, with each dose consisting of two 15-microgram intramuscular injections
Study: NCT01724190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04694638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body position change
Description: combined use of prone positioning and high-flow nasal cannula (HFNC) and non-invasive positive pressure ventilation (NIPPV) can reduce the rate of intubation in acute hypoxemic and/or hypercapnic respiratory failure secondary to COVID-19 infection.
Study: NCT02347865

Intervention type: DRUG
Intervention: AMG 162 - Prolia
Description: 500 patients
Study: NCT02373930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
Study: NCT02347865

Intervention type: DRUG
Intervention: AMG 162 - Prolia
Description: 250 patients, one year later
Study: NCT02373930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
Study: NCT03144206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period
Study: NCT03243890

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 720 µg/day including the recommended daily dose of vitamin D (25 µg/day).
Description: Half of the patients are randomized to supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day).
Study: NCT02373930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
Study: NCT03243890

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of the patients are randomized to placebo treatment (no active treatment).
Study: NCT01149252

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psoralait
Description: Cream to be used as instructed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream.
Description: Cream to be used as instructed
Study: NCT00442689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: 250 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 35 mcg and drospirenone 3 mg
Description: one active pill per day for three weeks and then 1 sugar pill per day for one week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01784185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual bronchoscopy guided transbronchial needle aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endobronchial ultrasound guided transbronchial needle aspiration
Description: endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal lesions
Study: NCT01410604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet of 500 mg oral placebo every 12 hours for 3 months.
Study: NCT02027571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Description: ILI consists of weight loss ( \> 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
Study: NCT02373930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
Study: NCT02313597

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SETON
Description: In seton treatment, initially Hydrogen peroxide will be applied to the external opening with a 10-cc syringe, and the internal opening will be located by direct visualization of the anal canal via proctoscope. A probe will be inserted into the external opening and carefully maneuvered through the internal opening. Silk 1/0 suture will be then tied to the tip of the probe, which will be then squeezed out of the external opening. The suture will be then tied around the sphincter and through fistula tract. Later, the seton will be tightened at four-week intervals under local anesthesia until the suture cut through the sphincter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VAAFT
Description: Patients assigned to the VAAFT group will receive the following procedure. The external opening will be widened with a probe, and a fistulascope will be inserted to delineate the primary and secondary tracts and locate the internal opening. The internal opening will be then stitched with Vicryl™ (Polyglactin 910) 2-0 suture through the anal route with the help of a proctoscope. The tract of the fistula will be washed and debrided through the scope and cauterized. Finally, the external opening will be excised and will be sent for biopsy.
Study: NCT01264471

Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)

Intervention type: PROCEDURE
Intervention: Blood Collection
Description: Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.
Study: NCT02237274

Intervention type: OTHER
Group type: OTHER
Intervention: High altitude exposition
Description: High altitude exposition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High altitude exposition
Description: High altitude exposition
Study: NCT00448357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabbit anti-thymocyte globulin (ATG)
Description: .5 mg/kg on day -3 and 2.5 mg/kg on day -2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: minimum total cluster of differentiation (CD34+) cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: PK-targeted continuous IV infusion over 90 hours on Days -7 to -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 30 mg/m\^2/day x 5 days intravenous piggyback (IVPB) over 30 minutes on Days -7 through -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: The suggested starting dose is 0.03 mg/kg po bid starting on day -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: A minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and maximum of 8 x 10\^6 cells/kg will be infused on day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 5 mg/m\^2 on days +1, +3 and +6
Study: NCT02373930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AK
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AK
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AK
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AK
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AK
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AK
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Study: NCT03470766

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nevro Senza System (HF10 Therapy)
Description: Nevro 10kHz High Frequency Spinal Cord Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nevro Senza System (HF10 Therapy)
Description: Nevro 10kHz High Frequency Spinal Cord Stimulation
Study: NCT02087683

Intervention type: OTHER
Group type: OTHER
Intervention: Vitamin D Supplementation
Description: Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologist, whom will give them the vitamin supply for a month.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group (Placebo)
Description: Participants in this group will receive a placebo made of gelatin and corn oil per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologists, whom will give the vitamin supply for a month.
Study: NCT02373930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AR
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AR
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AR
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AR
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AR
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AR
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AR
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AR
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AR
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Study: NCT03215914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed 670G system
Description: Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels \< 70 mg/dl.
Study: NCT03370757

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3-hour bundled care
Description: Infants in the 3-hour bundled care group will receive diaper changes every 3 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 3 times per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-hour bundled care
Description: Infants in the 6-hour bundled care group will receive diaper changes every 6 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 4 times per week.
Study: NCT02014948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: The individuals who make up this group performed exercises for 10 consecutive sessions.
Study: NCT04813744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment
Study: NCT05726695

Intervention type: DIAGNOSTIC_TEST
Intervention: microRNA test
Description: Laboratory analysis for the detection of microRNA in blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: microRNA test
Description: Laboratory analysis for the detection of microRNA in blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart ultrasound examination
Description: Heart ultrasound examination will be performed as a standard cardiology examination.
Study: NCT00508508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response System
Description: Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Led Group Clinic Visits
Description: At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies.